Who was Brandon Smyth? US R&B singer passed away at age of 28 from pulmonary fibrosis

Brandon Smyth was signed to Motown Records and had worked with artists including 2 Chainz and Future. Brandon Smyth's older brother shared the news of his death on Instagram, saying he "never dreamed" of having to share such news.

Agencies
Brandon Smyth, a Rhythm & Blues (R&B) singer from the US, has died. He was diagnosed with pulmonary fibrosis and died at the age of 28 from respiratory failure. The news was broken by the singer’s elder brother Denzil on Instagram this morning. He thanked his fans for their love and support and said that Brandon was excited to see his fans create social media challenges for his new music single.

​Market trading guide: Zydus Lifesciences among 4 stock recommendations for Monday​
1/5

During the holiday-shortened week, Nifty ended at close to 17,800 points while Nifty Bank saw some pressure on the final session of the week and ended lower by 0.75%. “The coming week might conclude a road map for the markets till Dec 2022 since we have a mega event of the US Fed. In addition; RBI has scheduled additional MPC meeting on Nov 03, 2022,” said Mehul Kothari - AVP- Technical Research, Anand Rathi Shares & Stock Brokers.



Here are stock 4 recommendations for Monday:
During the holiday-shortened week, Nifty ended at close to 17,800 points while Nifty Bank saw some pressure on the final session of the week and ended lower by 0.75%. “The coming week might conclude ..
Read More
Buy near Rs 610
Target: Rs 645
Stop loss: Rs 590

On the daily scale; we are witnessing a trend line breakout above Rs 605. This breakout also resembles a bullish inverse head and shoulder pattern.

(Mehul Kothari - AVP- Technical Research, Anand Rathi Shares & Stock Brokers)

Buy near Rs 610Target: Rs 645Stop loss: Rs 590On the daily scale; we are witnessing a trend line breakout above Rs 605. This breakout also resembles a bullish inverse head and shoulder pattern.(Mehu..
Read More
Buy near Rs 236
Target: Rs 260
Stop loss: Rs 224

For the last three months; the stock has been trading in a band of Rs 238 - 208. During the last session, it confirmed a range breakout above Rs 238 along with decent volumes.

(Mehul Kothari - AVP- Technical Research, Anand Rathi Shares & Stock Brokers)


Buy near Rs 236Target: Rs 260Stop loss: Rs 224For the last three months; the stock has been trading in a band of Rs 238 - 208. During the last session, it confirmed a range breakout above Rs 238 alon..
Read More
Buying range: Rs 426-432
Target price: Rs 470
Stop loss: Rs 408

Zydus Lifesciences found support around the Rs 319 levels in May, which also roughly coincides with previous intermediate lows of the stock. The stock has subsequently risen and made higher bottoms in the last few months.

In the process, the stock has broken out of a tight range. Momentum readings like the 14-week RSI, too, are in rising mode and not overbought, which is encouraging.

With the intermediate technical setup too looking positive, we believe the stock has the potential to move higher in the coming weeks.

(Subash Gangadharan, Senior Technical and Derivative Analyst, HDFC Securities)
Buying range: Rs 426-432Target price: Rs 470Stop loss: Rs 408Zydus Lifesciences found support around the Rs 319 levels in May, which also roughly coincides with previous intermediate lows of the stoc..
Read More
Selling range-Rs 3,540-3,550 levels.
Downside target: Rs 3,400
Stop loss- Rs 3,640

Divis Lab is in a short-term downtrend as it has been making lower tops and lower bottoms for the last few weeks. On Friday, the stock broke the recent support of Rs 3,562, indicating the downtrend looks set to continue.

Technical indicators are giving negative signals as the stock is now trading below the 20-day and 50-day SMA. Momentum readings like the 14-day RSI are in decline mode, which implies potential for more downsides.

We therefore expect the stock to correct further in the coming sessions.

(Subash Gangadharan, Senior Technical and Derivative Analyst, HDFC Securities)

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)
Selling range-Rs 3,540-3,550 levels.Downside target: Rs 3,400Stop loss- Rs 3,640Divis Lab is in a short-term downtrend as it has been making lower tops and lower bottoms for the last few weeks. On Fr..
Read More

Brandon Smyth's career

Brandon Smyth was born in Florida.
He started his music career on YouTube. He used to upload song covers by artists like Frank Ocean and Michael Jackson to his channel.

Later, in 2012, he signed a deal with a music label named Motown Records.
Brandon released his debut single, "Leggo," in 2013 with 2 Chainz.
He recorded and released many songs and collaborated with artists like Future, Rick Ross, and Young Thug.
Twerkoholic was his best single released in 2013, which gained streams of over 20 million views on YouTube and over 13 million plays on Spotify.


ADVERTISEMENT

FAQs:

  1. What is pulmonary fibrosis?
    Brandon Smyth suffered from pulmonary fibrosis, a lung condition. In this situation, breathing becomes difficult as the lungs get scarred. It is a rare condition and is found in people under the age of 50. Up until now, there has been no known cause.
  2. When and how did Brandon Smyth die?
    The R&B singer lost his life to pulmonary fibrosis on November 17, 2022. His fans paid tribute to his music career. Especially, rapper Dirty 1000 gave his condolences to the family, and DJ Mad Skillz showed his love by mentioning that he was a talented brother.
Download
The Economic Times Business News App
for the Latest News in Business, Sensex, Stock Market Updates & More.
Download
The Economic Times News App
for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
READ MORE
ADVERTISEMENT

READ MORE:

LOGIN & CLAIM

50 TIMESPOINTS

More from our Partners

Loading next story
Business News › News › International › US News › Who was Brandon Smyth? US R&B singer passed away at age of 28 from pulmonary fibrosis
Text Size:AAA
Success
This article has been saved

*

+